Tiziana Life Sciences (TLSA) announces positive new biomarker data from a late-breaking poster titled “Nasal foralumab downregulates CSF inflammation and upregulates CSF neuroprotective proteomic pathways which correlate with PBR06-PET imaging in na-SPMS with PIRA,” which was presented by investigators from Brigham and Women’s Hospital, Boston, MA. Key findings include: Nasal foralumab treatment significantly reduced voxel-wise average PBR06-PET m-GALP z-scores in white matter and global brain regions, confirming decreased microglial activation. CSF proteomics showed downregulation of inflammatory biomarkers and upregulation of neuroprotective proteins. Strong positive correlations were observed between PET m-GALP z-scores and inflammatory CSF proteins. Negative correlations were seen with neuroprotective proteins. These biomarker changes occurred alongside clinical stabilization or improvement, with no serious treatment-related adverse events.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences’ Intranasal Foralumab MS Study Published in Leading Neurology Journal
- Tiziana Life Sciences announces publication of intranasal foralumab results
- Tiziana Life Sciences Raises $8.8 Million in Oversubscribed Direct Offering to Fund Phase 2 Trials
- Tiziana Life Sciences Raises Up to $17.6 Million in Insider-Led Direct Offering to Fund Phase 2 Trials
- Tiziana Life Sciences prices 6.4M shares at $1.25 in registered direct offering